查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561542

2024-2032 年胃轻瘫药物市场报告（依疾病类型、药物类别、配销通路和地区）

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2023年全球胃轻瘫药物IMARC Group规模达65亿美元。糖尿病性胃轻瘫盛行率的上升、药物开发技术的进步、医疗保健专业人员和患者意识的提高、医疗保健投资的快速增长、临床试验的增加、糖尿病和帕金森氏症等慢性病的激增以及监管支持是推动市场成长的一些因素。

胃轻瘫药物市场分析：

  • 主要市场驱动因素：糖尿病盛行率的增加大大增加了胃轻瘫的盛行率，推动了市场的成长。诊断解决方案的改进进一步支持了这一点，使患者能够及早识别疾病。此外，易患胃轻瘫的老年人口不断增加是推动市场向前发展的另一个因素。与此一致的是，先进给药系统的使用不断增加，以及医疗保健提供者和患者对胃轻瘫的认识不断提高，正在促进市场成长。此外，医疗基础设施的快速扩张，尤其是在发展中地区，以及政府对胃肠道研究的倡议和资助，正在创造积极的胃轻瘫药物市场前景。
  • 主要市场趋势：对个人化医疗的偏好转变是主要市场趋势之一。此外，机器学习（ML）和人工智慧（AI）在药物发现中的整合加快了新疗法开发的步伐，从而推动了市场的成长。此外，对微创手术（MIS）的需求不断增长，推动了先进药物输送系统的使用，这是推动市场扩张的另一个因素。此外，对门诊护理和家庭治疗的日益重视以及对胃轻瘫研究的投资不断增加正在促进市场成长。
  • 地理趋势：由于糖尿病盛行率迅速上升、先进治疗方法的不断发展以及强大的医疗基础设施，北美占据了最大的市场份额。根据胃轻瘫药物市场预测，由于德国、英国和法国等国家主要市场参与者的存在，欧洲也占有相当大的市场份额。在亚太地区，医疗保健投资的增加、患者数量的增加以及对胃轻瘫的认识的提高正在促进市场的成长。
  • 竞争格局：胃轻瘫药物产业的一些主要市场参与者包括 Abbott Laboratories、Abbvie Inc.、AstraZeneca Plc、Bausch Health Companies Inc.、Becton Dickinson and Company、Boston Scientific Corporation、Evoke Pharma、Medtronic plc、Neurogastrx Inc.、赛诺菲(Sanofi SA)、武田药品工业株式会社(Takeda Pharmaceutical Company Limited) 和Theravance Biopharma 等。
  • 挑战与机会：根据市场概况，胃轻瘫药物市场主要受到对病理生理学的有限了解以及与现有药物相关的副作用的限制。然而，生物技术和基因组学的快速进步以及新标靶疗法的开发为市场扩张提供了利润丰厚的机会。此外，全球胃轻瘫诊断的改善和糖尿病病例的不断增加正在刺激市场成长。

胃轻瘫药物市场趋势：

胃轻瘫盛行率增加

胃轻瘫盛行率不断上升，尤其是糖尿病患者，正在加速市场成长。 2021年，印度约有7,490万年龄在20-79岁之间的糖尿病患者，预计到2045年将达到1.249亿。了为市场成长带来了巨大的推动力。此外，主要製药公司正在积极致力于开发新的标靶治疗方案，这进一步为市场创造了积极的前景。

药物开发技术的进步

管道中产品数量的不断增加以及新产品变体的开发正在促进市场成长。此外，为提高胃轻瘫疗法的疗效和安全性而对药物研发（R＆D）的投资激增正在推动市场成长。胃轻瘫药物市场最近的机会，例如高通量筛选、计算和个人化医疗的出现，使得能够精确、快速地识别潜在候选药物，正在为市场成长提供动力。除此之外，药物输送系统的进步，例如缓释製剂和新型药物输送机制，正在实现药物的有效给药和吸收，推动市场成长。

医疗保健专业人员和患者的意识不断提高

医疗保健专业人员和患者对胃轻瘫的认识不断增强，大大促进了市场的成长。由于随后意识的提高，患者得到了更准确的诊断，这进一步为市场成长提供了相当大的推动力。此外，胃肠病学家等医疗保健专业人员越来越敏锐地意识到这些症状，这进一步有助于更快地识别胃轻瘫，从而更好地照顾患者。此外，患者对胃轻瘫症状和治疗的认识不断提高，以及新型治疗方案的出现，正在推动胃轻瘫药物的需求。

胃轻瘫药物市场细分：

IMARC Group提供了每个细分市场的主要趋势的分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据疾病类型、药物类别和配销通路对市场进行了分类。

按疾病类型细分：

  • 糖尿病胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫
  • 其他的

特发性胃轻瘫占大部分市场份额

该报告根据疾病类型对市场进行了详细的细分和分析。这包括糖尿病性胃轻瘫、特发性胃轻瘫、术后胃轻瘫等。根据该报告，特发性胃轻瘫占最大部分。

特发性胃轻瘫领域的发展是由于人们越来越认识到该疾病的影响以及对有效治疗解决方案的需求。特发性胃轻瘫无法确定根本原因，由于其不可预测的性质和严重程度，给患者和医疗保健提供者带来了重大挑战。临床医生对特发性胃轻瘫的认识和理解的提高使得诊断更加准确，并专注于开发标靶治疗。诊断技术的进步，例如改进的影像和运动测试，正在增强识别特发性胃轻瘫病例并将其与其他胃肠道疾病区分开来的能力，从而促进胃轻瘫药物市场的成长。此外，针对特发性胃轻瘫的研究经费和临床试验的增加正在推动药物开发的创新，带来新的治疗选择。

按药物类别细分：

  • 促动力剂
  • 止吐剂
  • 肉毒桿菌注射

促动力剂占据产业最大份额

报告还提供了基于药物类别的详细市场细分和分析。这包括促动力剂、止吐剂和肉毒桿菌注射。报告称，促动力剂占据最大的市场份额。

胃轻瘫药物市场中的促胃动力药物细分市场是由几个关键因素驱动的，例如胃轻瘫盛行率不断增加，特别是在糖尿病和老年人群中，这对有效的促胃动力疗法产生了强烈需求。促动力剂可增强胃动力并促进胃排空，对于控制胃轻瘫症状（包括噁心和呕吐）至关重要。药物开发的重大进步导致促胃动力配方的改进、功效增强和副作用减少，从而增加了胃轻瘫药物市场收入。正在进行的针对促动力剂的研究和临床试验有助于更好地了解其机制和潜在益处，从而扩大其临床应用。此外，医疗保健专业人员和患者对胃轻瘫的认识不断增强，强调了对有效治疗的需求，进一步推动了对促胃动力药物的需求。

按配销通路划分：

  • 医院和诊所
  • 药局
  • 网上商店

医院和诊所是主要的细分市场

该报告根据配销通路对市场进行了详细的细分和分析。这包括医院和诊所、药房和网上商店。报告称，医院和诊所是最大的部分。

胃轻瘫药物市场的医院和诊所部分是由对治疗胃轻瘫的专业医疗护理和先进治疗选择不断增长的需求所推动的。该细分市场受益于胃轻瘫盛行率的不断上升，特别是在糖尿病患者中，因此需要更全面和更频繁的医疗干预措施。医院和诊所提供一系列诊断和治疗服务，包括专门的胃肠病科和先进的影像技术，这对于胃轻瘫的准确诊断和有效管理至关重要。此外，糖尿病和帕金森氏症等慢性疾病的增加（通常导致胃轻瘫）进一步推动了对医院治疗的需求。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美市场领先，胃轻瘫药物市占率最大

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是胃轻瘫药物最大的区域市场。

北美区域市场受到胃轻瘫盛行率迅速上升的推动，尤其是在糖尿病族群中，这极大地影响了对有效治疗的需求。糖尿病的高发生率是一个主要因素，因为糖尿病胃轻瘫是一种常见的併发症。此外，胃轻瘫药物市场的最新发展和进步，例如高通量筛选和新型药物输送系统，提高了胃轻瘫药物的功效和安全性，有助于市场扩张。除此之外，该地区还受益于强大的医疗基础设施和对研发的大量投资，从而能够更快地推出创新疗法。此外，医疗保健专业人员和患者对胃轻瘫及其管理的认识不断提高，正在加强市场成长，从而实现更早的诊断和更积极的治疗方法。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

  • 主要胃轻瘫药物公司正在积极参与多项策略性倡议，以提升其地位并满足对有效治疗日益增长的需求。他们正在大力投资研发 (R&D)，以发现和开发更有效地针对胃轻瘫潜在机制的新药。这些公司专注于创新药物配方，包括缓释和新型递送系统，以提高治疗的功效和患者的依从性。我们正在寻求与研究机构和学术组织的合作和伙伴关係，以利用外部专业知识和资源，从而加速新疗法的开发。此外，领先企业正在扩大其临床试验计划，以测试新的候选药物并收集关键资料以支持监管部门的批准。他们也积极寻求监管支持，以加快新疗法的审批流程，旨在更快地将创新解决方案推向市场。

胃轻瘫药物市场新闻：

  • 2023 年，专注于治疗胃肠道 (GI) 疾病的专业製药公司 Evoke Pharma 宣布其药物 GIMOTI 的一项新专利已在 FDA 橙皮书中列出。该专利名为“甲氧氯普胺鼻用配方”，将GIMOTI 的专利保护期限延长至2029 年。其在治疗糖尿病胃轻瘫的市场中的地位。
  • 2023 年，Enterra Medical 宣布其 Enterra(R) II 系统已获得 FDA 批准用于 MR 有条件使用。这种先进的胃轻瘫治疗方法包括 Enterra 37800 神经刺激器和 Enterra Therapy 4351-35 单极导线，现在允许患者在特定条件下接受头部和四肢的 MRI 扫描。

本报告回答的关键问题

  • 2023年全球胃轻瘫药物市场规模是多少
  • 2024-2032年全球胃轻瘫药物市场的预期成长率是多少
  • COVID-19 对全球胃轻瘫药物市场有何影响
  • 推动全球胃轻瘫药物市场的关键因素是什么
  • 根据疾病类型，全球胃轻瘫药物市场的细分如何
  • 根据药物类别，全球胃轻瘫药物市场的细分如何
  • 基于配销通路，全球胃轻瘫药物市场的细分如何
  • 全球胃轻瘫药物市场的重点区域有哪些
  • 谁是全球胃轻瘫药物市场的主要参与者/公司

本报告回答的关键问题

  • 2023年全球胃轻瘫药物市场规模？ 2024-2032年全球胃轻瘫药物市场的预期成长率为何？
  • COVID-19 对全球胃轻瘫药物市场有何影响？
  • 推动全球胃轻瘫药物市场的关键因素是什么？
  • 根据疾病类型，全球胃轻瘫药物市场的细分如何？
  • 根据药物类别，全球胃轻瘫药物市场的细分如何？
  • 根据配销通路，全球胃轻瘫药物市场的细分如何？
  • 全球胃轻瘫药物市场的重点区域有哪些？
  • 全球胃轻瘫药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球胃轻瘫药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疾病类型

  • 糖尿病胃轻瘫
    • 市场趋势
    • 市场预测
  • 特发性胃轻瘫
    • 市场趋势
    • 市场预测
  • 术后胃轻瘫
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依药物类别

  • 促动力剂
    • 市场趋势
    • 市场预测
  • 止吐剂
    • 市场趋势
    • 市场预测
  • 肉毒桿菌注射
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院和诊所
    • 市场趋势
    • 市场预测
  • 药局
    • 市场趋势
    • 市场预测
  • 网上商店
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
Product Code: SR112024A4608

The global gastroparesis drugs market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth.

Gastroparesis Drugs Market Analysis:

  • Major Market Drivers: The increasing prevalence of diabetes has considerably boosted the prevalence of gastroparesis, which is fueling the market growth. This is further supported by the improvements in diagnosis solutions, which enable early disease identification among patients. Moreover, the escalating geriatric population susceptible to gastroparesis is another factor propelling the market forward. In line with this, the growing use of advanced drug delivery systems and surging awareness about gastroparesis among healthcare providers and patients are facilitating the market growth. Furthermore, the rapid expansion of healthcare infrastructure, especially in developing regions, and government initiatives and funding for gastrointestinal research are creating a positive gastroparesis drugs market outlook.
  • Key Market Trends: The shifting preference toward personalized medicine is one of the primary market trends. Moreover, the integration of machine learning (ML) and artificial intelligence (AI) in drug discovery to boost the pace of novel therapy development is bolstering the market growth. Additionally, the increasing demand for minimally invasive surgery (MIS) has fueled the use of advanced drug delivery systems, which is another factor driving market expansion. Furthermore, the escalating emphasis on outpatient care and home-based treatments and burgeoning investments in gastroparesis research are facilitating the market growth.
  • Geographical Trends: North America holds the largest market share due to the burgeoning prevalence of diabetes, the continuous development of advanced treatments, and the presence of robust healthcare infrastructure. As per the gastroparesis drugs market forecast, Europe also holds a considerable market share backed by the presence of key market players in countries, such as Germany, the UK, and France. In the Asia Pacific, rising healthcare investments, growing patient numbers, and increasing awareness regarding gastroparesis are fostering the market growth.
  • Competitive Landscape: Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Theravance Biopharma, among many others.
  • Challenges and Opportunities: As per the market overview, the gastroparesis drugs market is primarily restrained by the limited understanding of pathophysiology and the side effects associated with currently available medications. However, the rapid advancement in biotechnology and genomics and the development of new targeted therapies are presenting lucrative opportunities for market expansion. Furthermore, the improving diagnosis of gastroparesis and burgeoning cases of diabetes across the globe are stimulating the market growth.

Gastroparesis Drugs Market Trends:

Increasing Prevalence of Gastroparesis

The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.

Advancements in Drug Development Technologies

The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.

Rising Awareness Among Healthcare Professionals and Patients

The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.

Gastroparesis Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on disease type, drug class, and distribution channel.

Breakup by Disease Type:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Idiopathic gastroparesis accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others. According to the report, idiopathic gastroparesis represented the largest segment.

The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.

Breakup by Drug Class:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Prokinetic agents hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes prokinetic agents, antiemetic agents, and botulinum toxin injections. According to the report, prokinetic agents accounted for the largest market share.

The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Pharmacies
  • Online Stores

Hospitals and clinics represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospitals and clinics, pharmacies, and online stores. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest gastroparesis drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.

The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The key gastroparesis drugs companies are actively engaged in several strategic initiatives to advance their position and address the growing demand for effective treatments. They are investing heavily in research and development (R&D) to discover and develop new drugs that target the underlying mechanisms of gastroparesis more effectively. These companies are focusing on innovative drug formulations, including extended-release and novel delivery systems, to enhance the efficacy and patient compliance of treatments. Collaborations and partnerships with research institutions and academic organizations are being pursued to leverage external expertise and resources, which accelerates the development of new therapies. Additionally, leading players are expanding their clinical trial programs to test new drug candidates and gather crucial data to support regulatory approvals. They are also actively seeking regulatory support to expedite the approval process for new treatments, aiming to bring innovative solutions to market more quickly.

Gastroparesis Drugs Market News:

  • In 2023, Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced the FDA Orange Book listing of a new patent for their drug GIMOTI. The patent, titled "Nasal Formulations of Metoclopramide," extends GIMOTI's patent protection through 2029. This addition marks the fourth patent listed for GIMOTI, enhancing its intellectual property portfolio, and securing its position in the market for treating diabetic gastroparesis.
  • In 2023, Enterra Medical announced that its Enterra(R) II System received FDA approval for MR Conditional use. This advanced treatment for gastroparesis, which includes the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, now allows patients to undergo MRI scans of the head and extremities under specific conditions.

Key Questions Answered in This Report

  • 1. What was the size of the global gastroparesis drugs market in 2023?
  • 2. What is the expected growth rate of the global gastroparesis drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4. What are the key factors driving the global gastroparesis drugs market?
  • 5. What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6. What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7. What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8. What are the key regions in the global gastroparesis drugs market?
  • 9. Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players